Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile

BackgroundBiosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilarity, immunogenicity assessments were performed in h...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Paul Chamberlain, Bernhard Hemmer, Josef Höfler, Hendrik Wessels, Oliver von Richter, Cyrill Hornuss, Johann Poetzl, Karsten Roth
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Subjects:	natalizumab multiple sclerosis neutralizing antibodies anti-drug antibodies immunology biologic products
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1414304/full